DESMODA is the first and only FDA-approved desmopressin oral solutionCommercial launch expected on March 9thDESMODA eliminates tablet splitting and crushing, enabling precise, individualized dosing for patients of all agesThe product is expected to be a significant long-term growth contributor, with potential peak sales of $30-50 million annually and patent protection extending through 2044 DEER PARK, Ill., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), ...

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #CROI2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new Phase 3 ARTISTRY-1 and ARTISTRY-2 trial data at CROI 2026 showing a treatment switch to an investigational, single-tablet combination regimen of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) was effective in people living with HIV with virological suppression, including those switching from complex multi-tablet regimens or a global guideline-recommended single-tablet regimen. The n. ...

Summary of Zentalis Pharmaceuticals FY Conference Call Company Overview - **Company**: Zentalis Pharmaceuticals (NasdaqGM:ZNTL) - **Focus**: Development of azenosertib, an oral non-chemotherapy treatment for biomarker-selected cancer patients Key Points Clinical Data and Treatment Efficacy - Azenosertib has shown a response rate over 30% and a duration of response of approximately 6 months in clinical trials, which is significantly better than single-agent chemotherapy with low double-digit response rates and short duration [2][3] - Over 500 patients have been treated with azenosertib, either as a monotherapy or in combination, demonstrating clear activity in patients who have failed other treatment options [4] - The DENALI trial is a multi-stage clinical program aimed at potential accelerated approval for azenosertib in PROTAC Cyclin E1-positive patients, with enrollment ongoing and expected to complete by year-end [5][6] Regulatory Pathway and FDA Interaction - The FDA has provided guidance on the accelerated approval pathway, emphasizing the need for a confirmatory randomized trial alongside the DENALI trial [9][10] - The ASPENOVA trial, a Phase 3 confirmatory study against single-agent chemotherapy, is designed to support full approval in the same patient population [5][6] Competitive Landscape - There is increasing competition in the market, particularly from antibody-drug conjugates (ADCs) targeting Folate receptor alpha, which may work regardless of biomarkers [7] - Azenosertib is positioned as a non-chemotherapy option that offers convenience and improved quality of life for patients, as it is an oral treatment compared to traditional IV chemotherapy [11][13] Biomarker Significance - Cyclin E1 overexpression is being studied as a biomarker for patient selection, with both gene amplification and high protein expression correlating to treatment response [29][30] - The DENALI trial includes prospective screening to validate the biomarker, with a focus on ensuring that patients who could benefit are not missed [34] Safety and Tolerability - Azenosertib is considered to have a manageable and well-tolerated safety profile compared to alternatives, with low discontinuation rates due to adverse events [46][48] - The trial management approach has been refined to enhance patient safety and support, which is expected to improve outcomes [39][40] Future Expectations - The company anticipates that the data from the ongoing trials will support the efficacy and safety of azenosertib, potentially leading to improved outcomes compared to previous trials [35][39] - The ASPENOVA trial design is similar to the successful MIRASOL trial, with an adaptive dose randomization to accelerate the process [50] Conclusion - Zentalis Pharmaceuticals is positioned for a pivotal year with the ongoing trials of azenosertib, which could provide a significant advancement in treatment options for patients with specific cancer biomarkers, while also addressing the need for more convenient and less toxic therapies [54]

Summary of Oric Pharmaceuticals FY Conference Call Company Overview - **Company**: Oric Pharmaceuticals (NasdaqGS:ORIC) - **Industry**: Clinical stage oncology - **Focus Areas**: Prostate cancer, lung cancer, and breast cancer [2][3] Key Programs 1. **Rinzimetostat (ORIC-944)**: - Allosteric PRC2 inhibitor targeting prostate cancer in combination with AR inhibitors (apalutamide and darolutamide) [2][3] - Phase III study expected to start in the first half of 2026 [3][4] - Early clinical data shows promising PSA response rates and favorable safety profile compared to Pfizer's data [5][17] 2. **Enosertinib**: - EGFR inhibitor with high potency on exon 20 and PAK mutations [3][43] - Demonstrated 100% overall response rate in patients with measurable disease, including those with untreated brain metastases [43] Market Opportunity - **Prostate Cancer**: - Large patient population with significant unmet needs; over $11 billion in sales for ARPi inhibitors last year [23][24] - Potential to reverse resistance to current therapies and extend treatment duration [24][25] - **Lung Cancer**: - High prevalence of CNS metastases in lung cancer patients, making CNS activity a critical differentiator for enosertinib [43][44] Competitive Landscape - **Rinzimetostat vs. Mevrometostat**: - Rinzimetostat is positioned as a potentially best-in-class PRC2 inhibitor with better drug properties, including solubility and half-life [11][12] - Early data suggests lower rates of gastrointestinal and hematological toxicities compared to competitors [17] - **Enosertinib's Differentiation**: - Focus on CNS activity and less off-target toxicities compared to competitors [43][44] Upcoming Milestones - **Rinzimetostat**: - Q1 update with data from 20-25 patients expected, focusing on PSA50, PSA90, safety, and tolerability [38][39] - Phase III study initiation in the first half of 2026 [3][38] - **Enosertinib**: - Continued evaluation of monotherapy and combination strategies, with updates expected in the second half of 2026 [48][49] Investor Considerations - The stock's performance is closely tied to the outcomes of the MEVPRO-1 study and the company's own data releases [53][56] - Rinzimetostat is viewed as a potential blockbuster if it demonstrates differentiation in safety and efficacy [58] Conclusion Oric Pharmaceuticals is strategically positioned in the oncology space with promising drug candidates targeting significant unmet needs in prostate and lung cancers. The upcoming data releases and competitive positioning will be critical for investor confidence and stock performance moving forward.

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) on Wednesday reported a fourth quarter adjusted loss of $1.15, better than the Wall Street loss estimate of $1.32 • Ionis Pharmaceuticals stock is showing notable weakness. What’s pressuring IONS stock?Sales reached $203 million, beating the consensus of $156.09 million.Commercial revenue for the fourth quarter and the year ended Dec. 31, 2025, increased 64% and 49%, respectively, compared to the same periods in 2024.Tryngolza (olezarsen) product sales primarily drov ...

Merck's two-drug HIV regimen matched Gilead's blockbuster Biktarvy in Phase 3 trials and is under FDA review as the company prepares for Keytruda's patent cliff. ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from three pivotal Phase 3 trials evaluating the investigational, once-daily, oral, two-drug regimen of doravirine/islatravir [DOR/ISL (100 mg/0.25 mg), (MK- 8591A)] in adults with HIV-1. The findings were shared in late-breaking presentations at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI) being held in Denver. "We are proud to contin ...

Ironwood Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Execution and Performance Drivers Delivered 11% LINZESS prescription demand growth in 2025, maintaining a 45% market share despite net price erosion from Medicare Part D redesign. Strategic reduction of LINZESS list price effective January 1, 2026, was implemented to preserve broad patient access amid evolving healthcare dynamics. Secured FDA alignment on the STARS II confirmatory Phase III trial for aproglutide, leveragin ...

Management acknowledged potential generic competition for VIVITROL in 2027, noting the product's manufacturing complexity as a significant barrier to entry for competitors.The expiration of Zeppelin royalties in the second half of 2026 is expected to create a headwind for manufacturing and royalty revenue streams.VIVITROL and ARISTADA 2025 results included $27M and $14M respectively in one-time gross-to-net favorability that management explicitly stated will not recur in 2026.A non-cash inventory step-up ch ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券简称：康缘药业 证券代码：600557 公告编号：2026-004 江苏康缘药业股份有限公司 关于收到黑黄赤珠颗粒临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 江苏康缘药业股份有限公司（以下简称"公司"）近日收到国家药品监督管理局签发的黑黄赤珠颗粒《药 物临床试验批准通知书》。按照《上海证券交易所上市公司自律监管指引第3号一行业信息披露》的相 关要求，现将相关情况公告如下： 一、《药物临床试验批准通知书》主要内容 ■ 黑黄赤珠颗粒审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025年12月2日受 理的黑黄赤珠颗粒（CXZL2500124）临床试验申请符合药品注册的有关要求，在进一步完善临床试验 方案的基础上，同意本品开展用于慢性心力衰竭的临床试验。 二、药品研发及相关情况 黑黄赤珠颗粒功能主治为益气活血、通阳利水。用于缺血性心脏病引起的慢性心力衰竭气阳虚血瘀水泛 证，症见心悸气短、喘息、胸闷、胸痛、疲倦乏力、面肢浮肿、尿少、咳嗽 ...